KAHR Bio key facts
as of Oct 2026- Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack.
- KAHR Bio is valued at approximately $165.7M as of Oct 2026 (last reported valuation).
- It has raised $183.3M; the latest was Later Stage VC ($32.0M) in Sep 2025.
- Notable investors include Korea Investment Partners, Innovation Authority, Peregrine Ventures, SPRIM Global Investments, Consensus Business Group — 19 tracked in total.
- Status: Privately Held (backing).
KAHR Bio's last reported valuation, Nov 2022. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch KAHR Bio: the Monday email on marks, rounds and moves
KAHR Bio funding rounds
No funding rounds for KAHR Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs KAHR Bio
19+KAHR Bio valuation
KAHR Bio's last reported valuation was $166 million in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.
KAHR Bio investors
19 investors are on record for KAHR Bio, including Korea Investment Partners, Innovation Authority, Peregrine Ventures and SPRIM Global Investments.
About KAHR Bio
Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack. The company specializes in the multifunctional immuno-recruitment protein technology to overcome the ability of cancers to evade recognition and elimination by the immune system, enabling doctors to help reduce patients' cancer cells.
- Sector
- Healthcare
- HQ
- Modi'in Makabim-Re'ut, Israel
- Founded
- 2005
- Employees
- 23
- Website
- kahrbio.base44.app/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.